Logo

Dharmacon to Provide More siRNAs to Bayer

Mar 02, 2004

NEW YORK, March 2 (GenomeWeb News) - Dharmacon will supply Bayer Pharmaceuticals with siRNA reagents for 4,000 gene targets by the end of March, the company said today.

 

The agreement expands an existing contract the companies announced in November. Bayer plans to use the custom siRNA reagents for internal target validation research.

 

Last month, Fisher Scientific International said it will acquire Lafayette, Colo.-based Dharmacon for $80 million in cash.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.